Dr. Daniele on Impact of Regorafenib in HCC

Bruno Daniele, MD
Published: Friday, Jul 08, 2016


Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Regorafenib will change the treatment landscape because it significantly increases survival in patients, Daniele explains.

However, it is important to note the therapeutic sequence of systemic therapy because, overall, the combination of sorafenib (Nexavar) and regorafenib in sequence is associated with a median overall survival of 26 months.
 

<<< View more from the 2016 World Congress on GI Cancer


Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Regorafenib will change the treatment landscape because it significantly increases survival in patients, Daniele explains.

However, it is important to note the therapeutic sequence of systemic therapy because, overall, the combination of sorafenib (Nexavar) and regorafenib in sequence is associated with a median overall survival of 26 months.
 

<<< View more from the 2016 World Congress on GI Cancer


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x